IMMX
Immix BiopharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IMMX Profile
Immix Biopharma, Inc.
A biopharmaceutical company that researches and develops drugs and therapies in the fields of oncology and inflammation
11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064
--
Immix Biopharma, Inc., was incorporated as a Delaware corporation on January 7, 2014. The Company is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy (" CAR-T ") in light chain (AL) amyloidosis and autoimmune diseases. The Company's lead cell therapy drug candidate is CAR-T NXC-201, approved by the U.S. Food and Drug Administration (" FDA ") as an investigational new drug (" IND "), and is currently being evaluated in the Company's Phase 1 b/2 a NEXICART-1 (NCT04720313) clinical trial.
